Diagnosis of multiple sclerosis: progress and challenges

The Lancet

Volumn 389, Issue 10076, 2017, Pages 1336-1346

  Brownlee, Wallace J ^a   Hardy, Todd A ^b   Fazekas, Franz ^c   Miller, David H ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CLINICAL PRACTICE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; HUMAN; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; BRAIN; DIAGNOSTIC IMAGING; SPINAL CORD;

BRAIN; DIAGNOSIS, DIFFERENTIAL; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROMYELITIS OPTICA; SPINAL CORD;

EID: 85007256417     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30959-X     Document Type: Review

References (81)

1. 1 Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69 (2011), 292–302.
2. 2 Lublin, FD, Reingold, SC, Cohen, JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83 (2014), 278–286.
3. 3 Hirst, C, Ingram, G, Pickersgill, T, Swingler, R, Compston, DA, Robertson, NP, Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry 80 (2009), 386–391.
4. 4 Wingerchuk, DM, Banwell, B, Bennett, JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2015), 177–189.
5. 5 Brownlee, WJ, Miller, DH, Clinically isolated syndromes and the relationship to multiple sclerosis. J Clin Neurosci 21 (2014), 2065–2071.
6. 6 Miller, DH, Leary, SM, Primary-progressive multiple sclerosis. Lancet Neurol 6 (2007), 903–912.
7. 7 Offenbacher, H, Fazekas, F, Schmidt, R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 43 (1993), 905–909.
8. 8 Fisniku, LK, Brex, PA, Altmann, DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131 (2008), 808–817.
9. 9 Fazekas, F, Barkhof, F, Filippi, M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53 (1999), 448–456.
10. 10 Sombekke, MH, Wattjes, MP, Balk, LJ, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80 (2013), 69–75.
11. 11 Bot, JC, Barkhof, F, Lycklama a Nijeholt, G, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology 223 (2002), 46–56.
12. 12 Rovira, A, Wattjes, MP, Tintore, M, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11 (2015), 471–482.
13. 13 Garg, N, Reddel, SW, Miller, DH, et al. The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. J Neurol Neurosurg Psychiatry 86 (2015), 1374–1382.
14. 14 Freedman, MS, Thompson, EJ, Deisenhammer, F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62 (2005), 865–870.
15. 15 Dobson, R, Ramagopalan, S, Davis, A, Giovannoni, G, Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 84 (2013), 909–914.
16. 16 Leocani, L, Comi, G, Clinical neurophysiology of multiple sclerosis. Handb Clin Neurol 122 (2014), 671–679.
17. 17 Negrotto, L, Tur, C, Tintore, M, et al. Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Mult Scler 21 (2015), 1802–1810.
18. 18 Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983), 227–231.
19. 19 Brownlee, WJ, Swanton, JK, Altmann, DR, Ciccarelli, O, Miller, DH, Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria. J Neurol Neurosurg Psychiatry 86 (2015), 584–585.
20. 20 Montalban, X, Sastre-Garriga, J, Filippi, M, et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler 15 (2009), 1459–1465.
21. 21 Liu, S, Kullnat, J, Bourdette, D, et al. Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. Mult Scler 19 (2013), 1101–1105.
22. 22 Nielsen, JM, Korteweg, T, Barkhof, F, Uitdehaag, BM, Polman, CH, Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol 58 (2005), 781–783.
23. 23 Selchen, D, Bhan, V, Blevins, G, et al. MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary. Neurology 79 (2012), S1–15.
24. 24 Absinta, M, Rocca, MA, Colombo, B, et al. Patients with migraine do not have MRI-visible cortical lesions. J Neurol 259 (2012), 2695–2698.
25. 25 Montalban, X, Tintore, M, Swanton, J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (2010), 427–434.
26. 26 Patrucco, L, Rojas, JI, Miguez, JS, Cristiano, E, Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler 19 (2013), 1297–1301.
27. 27 Huh, SY, Kim, SH, Kim, W, et al. Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. Mult Scler 20 (2014), 492–495.
28. 28 Okuda, DT, Mowry, EM, Beheshtian, A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72 (2009), 800–805.
29. 29 Okuda, DT, Siva, A, Kantarci, O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One, 9, 2014, e90509.
30. 30 Lebrun, C, Bensa, C, Debouverie, M, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 66 (2009), 841–846.
31. 31 Giorgio, A, Stromillo, ML, Rossi, F, et al. Cortical lesions in radiologically isolated syndrome. Neurology 77 (2011), 1896–1899.
32. 32 Krupp, LB, Tardieu, M, Amato, MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19 (2013), 1261–1267.
33. 33 Chabas, D, Castillo-Trivino, T, Mowry, EM, Strober, JB, Glenn, OA, Waubant, E, Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?. Neurology 71 (2008), 1090–1093.
34. 34 Peche, SS, Alshekhlee, A, Kelly, J, Lenox, J, Mar, S, A long-term follow-up study using IPMSSG criteria in children with CNS demyelination. Pediatr Neurol 49 (2013), 329–334.
35. 35 Sadaka, Y, Verhey, LH, Shroff, MM, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 72 (2012), 211–223.
36. 36 Tremlett, H, Devonshire, V, Is late-onset multiple sclerosis associated with a worse outcome?. Neurology 67 (2006), 954–959.
37. 37 de Seze, J, Delalande, S, Michelin, E, et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol 12 (2005), 241–244.
38. 38 Wallner-Blazek, M, Rovira, A, Fillipp, M, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 260 (2013), 2016–2022.
39. 39 Seewann, A, Enzinger, C, Filippi, M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings. J Neurol 255 (2008), 1–10.
40. 40 Lucchinetti, CF, Gavrilova, RH, Metz, I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 (2008), 1759–1775.
41. 41 Hardy, TA, Reddel, SW, Barnett, MH, Palace, JDM, Lucchinetti, CF, Weinshenker, BG, Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol 15 (2016), 967–981.
42. 42 Miller, DH, Weinshenker, BG, Filippi, M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14 (2008), 1157–1174.
43. 43 Schwarz, S, Mohr, A, Knauth, M, Wildemann, B, Storch-Hagenlocher, B, Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56 (2001), 1313–1318.
44. 44 Trebst, C, Jarius, S, Berthele, A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261 (2014), 1–16.
45. 45 Zekeridou, A, Lennon, VA, Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e110.
46. 46 Pandit, L, Asgari, N, Apiwattanakul, M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21 (2015), 845–853.
47. 47 Kitley, J, Leite, MI, Nakashima, I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135 (2012), 1834–1849.
48. 48 Kimbrough, DJ, Fujihara, K, Jacob, A, et al. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord 1 (2012), 180–187.
49. 49 Kim, HJ, Paul, F, Lana-Peixoto, MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84 (2015), 1165–1173.
50. 50 Ramanathan, S, Prelog, K, Barnes, EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22 (2016), 470–482.
51. 51 Matthews, L, Marasco, R, Jenkinson, M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80 (2013), 1330–1337.
52. 52 Jarius, S, Paul, F, Franciotta, D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306 (2011), 82–90.
53. 53 Waters, PJ, McKeon, A, Leite, MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78 (2012), 665–671.
54. 54 Pittock, SJ, Lennon, VA, Bakshi, N, et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 71 (2014), 1433–1436.
55. 55 Kister, I, Paul, F, Pushing the boundaries of neuromyelitis optica: does antibody make the disease?. Neurology 85 (2015), 118–119.
56. 56 Kitley, J, Woodhall, M, Waters, P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79 (2012), 1273–1277.
57. 57 Kitley, J, Waters, P, Woodhall, M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71 (2014), 276–283.
58. 58 Kim, SM, Woodhall, MR, Kim, JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e163.
59. 59 Hacohen, Y, Absoud, M, Deiva, K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e81.
60. 60 Reindl, M, Rostasy, K, MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e60.
61. 61 Flanagan, EP, Weinshenker, BG, Krecke, KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 72 (2015), 81–87.
62. 62 Costa, C, Arrambide, G, Tintore, M, et al. Value of NMO-IgG determination at the time of presentation as CIS. Neurology 78 (2012), 1608–1611.
63. 63 Solomon, AJ, Weinshenker, BG, Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. Curr Neurol Neurosci Rep, 13, 2013, 403.
64. 64 Solomon, AJ, Klein, EP, Bourdette, D, “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology 78 (2012), 1986–1991.
65. 65 Hutchinson, M, Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary. Mult Scler 20 (2014), 1690–1691.
66. 66 Hutchinson, M, CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Commentary. Mult Scler 19 (2013), 719–720.
67. 67 Swanton, JK, Fernando, KT, Dalton, CM, et al. Early MRI in optic neuritis: The risk for disability. Neurology 72 (2009), 542–550.
68. 68 Filippi, M, Rocca, MA, Ciccarelli, O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15 (2016), 292–303.
69. 69 US Food and Drug Administration. FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). http://www.fda.gov/Drugs/DrugSafety/ucm455386.htm (accessed Nov 8, 2016).
70. 70 European Medicines Agency. EMA reviewing gadolinium contrast agents used in MRI scans. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f (accessed Nov 8, 2016).
71. 71 Chard, DT, Dalton, CM, Swanton, J, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 82 (2011), 176–179.
72. 72 Sormani, MP, Tintore, M, Rovaris, M, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol 64 (2008), 42–43.
73. 73 Filippi, M, Rocca, MA, Calabrese, M, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 75 (2010), 1988–1994.
74. 74 Brownlee, WJ, Swanton, JK, Miszkiel, KA, Miller, DH, Ciccarelli, O, Should the symptomatic region be included in dissemination in space in MRI criteria for MS?. Neurology 87 (2016), 680–683.
75. 75 Sethi, V, Yousry, TA, Muhlert, N, et al. Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 83 (2012), 877–882.
76. 76 Sinnecker, T, Dorr, J, Pfueller, CF, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 79 (2012), 708–714.
77. 77 Tallantyre, EC, Morgan, PS, Dixon, JE, et al. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Invest Radiol 44 (2009), 491–494.
78. 78 Kister, I, Herbert, J, Zhou, Y, Ge, Y, Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica. Mult Scler Int, 2013, 2013, 398259.
79. 79 Teunissen, CE, Malekzadeh, A, Leurs, C, Bridel, C, Killestein, J, Body fluid biomarkers for multiple sclerosis—the long road to clinical application. Nat Rev Neurol 11 (2015), 585–596.
80. 80 Bennett, JL, de Seze, J, Lana-Peixoto, M, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler 21 (2015), 678–688.
81. 81 Ringelstein, M, Albrecht, P, Kleffner, I, et al. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology 85 (2015), 610–618.